Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Consensus Target Price from Brokerages
Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) have earned a consensus rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to […]
Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) have earned a consensus rating of “Hold” from the seven research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to […]
